FEMY

Femasys Inc.
CAPPED RATING

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Femasys Inc. (FEMY) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (D-). The rating has held at C+ for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.6 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
B
Factor Score 3.2 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
D-
Factor Score 1.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.7
EV / EBITDA -0.9
Rev Growth YoY -18.9%
Gross Margin 60.9%
Price Return 3M -39.1%
Price Return 12M -93.1%
Catalyst Signal 0.00
Market Cap $12.0M
TTM Revenue $2.3M
Price / Sales 5.2
ROE -425.0%

Historical Factor Score Progression

Held C+ for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (3.0) B (3.2) B- (3.0) D- (1.1) C+ (2.6) C+ (2.6)
2026-11-04 B- (3.0) B (3.2) B- (3.1) D- (0.8) C+ (2.7) C+ (2.5)
2026-10-28 B- (3.0) B (3.2) B- (3.1) D- (0.8) C+ (2.7) C+ (2.5)
2026-10-21 B- (3.0) B (3.2) B- (3.0) D- (0.7) C+ (2.6) C+ (2.5)
2026-10-14 B- (3.0) B (3.2) B- (3.0) D- (0.8) C+ (2.6) C+ (2.5)
Page 1 of 4